Higher levels of DNA2 expression were correlated with 1q21 amplification (Supplementary Fig. 3F) and poorer overall survival in MM patients treated with velcade, revlimid, and dexamethasone or high-dose chemotherapy followed by tandem autologous transplantation (Fig. 3D), proteasome inhibitors (PIs) alone or in combination with other therapies but not in those treated with immunomodulatory drugs (Supplementary Fig. 3G). The gene discussed is DNA2; the disease is Miyoshi myopathy.